Servier Commences Tender Offer to Acquire Day One Biopharmaceuticals for $2.5 Billion at $21.50 Per Share

summarizeSummary

Servier has officially launched its tender offer to acquire all shares of Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.51 billion and marking a significant premium for shareholders.

check_boxKey Events

• Tender Offer Commenced

  Servier Detroit Inc. has commenced a tender offer to acquire all outstanding shares of Day One Biopharmaceuticals, Inc. for $21.50 per share in cash. The offer is set to expire on April 22, 2026.

• Board Recommends Acceptance

  The Board of Directors of Day One Biopharmaceuticals has unanimously recommended that shareholders accept the offer and tender their shares, deeming the transaction fair and in the best interests of the company and its stockholders.

• Significant Premium and Valuation

  The $21.50 per share offer price represents a substantial premium over the company's closing price of $12.78 on March 5, 2026, prior to the merger agreement announcement. The total transaction value is approximately $2.51 billion.

• Company to Go Private

  Upon successful completion of the tender offer and subsequent merger, Day One Biopharmaceuticals will become a wholly-owned subsidiary of Servier and its shares will be delisted from The Nasdaq Global Select Market.

auto_awesomeAnalysis

Servier Detroit Inc., a subsidiary of Servier S.A.S., has formally commenced its tender offer to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share in cash. This follows the initial announcement of the merger agreement on March 6, 2026, and the SC TO-C filing on March 23, 2026. The offer price represents a substantial premium over the company's closing price of $12.78 on March 5, 2026, before the merger agreement was publicly announced, and is slightly above the current trading price and 52-week high. The total transaction value, including outstanding options, restricted stock units, and pre-funded warrants, is approximately $2.51 billion. The Board of Directors of Day One Biopharmaceuticals has unanimously recommended that shareholders accept the offer. Upon successful completion of the tender offer and subsequent merger, Day One Biopharmaceuticals will become a private, wholly-owned subsidiary of Servier and will be delisted from Nasdaq. This is a definitive, thesis-altering event for shareholders.